JPH0497747A - Artificial bone for transplanting application - Google Patents
Artificial bone for transplanting applicationInfo
- Publication number
- JPH0497747A JPH0497747A JP21594890A JP21594890A JPH0497747A JP H0497747 A JPH0497747 A JP H0497747A JP 21594890 A JP21594890 A JP 21594890A JP 21594890 A JP21594890 A JP 21594890A JP H0497747 A JPH0497747 A JP H0497747A
- Authority
- JP
- Japan
- Prior art keywords
- bone
- powder
- binder
- coating
- osteogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 91
- 239000000843 powder Substances 0.000 claims abstract description 40
- 238000000576 coating method Methods 0.000 claims abstract description 32
- 239000011230 binding agent Substances 0.000 claims abstract description 29
- 239000011248 coating agent Substances 0.000 claims abstract description 29
- 239000002245 particle Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 230000002188 osteogenic effect Effects 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 6
- 230000001054 cortical effect Effects 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000005667 attractant Substances 0.000 claims description 2
- 235000015115 caffè latte Nutrition 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229920006030 multiblock copolymer Polymers 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000000010 osteolytic effect Effects 0.000 claims description 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229920001651 Cyanoacrylate Polymers 0.000 claims 1
- 229920002732 Polyanhydride Polymers 0.000 claims 1
- 230000004956 cell adhesive effect Effects 0.000 claims 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 claims 1
- 210000004292 cytoskeleton Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 150000002905 orthoesters Chemical class 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000003014 reinforcing effect Effects 0.000 claims 1
- 239000012783 reinforcing fiber Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 16
- 239000002904 solvent Substances 0.000 abstract description 10
- 230000008468 bone growth Effects 0.000 abstract description 8
- 239000007943 implant Substances 0.000 abstract description 7
- 239000012528 membrane Substances 0.000 abstract description 5
- 210000000056 organ Anatomy 0.000 abstract description 2
- 230000011164 ossification Effects 0.000 abstract 4
- 230000006698 induction Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000008215 water for injection Substances 0.000 description 7
- 210000001624 hip Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 5
- 238000005238 degreasing Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 210000004394 hip joint Anatomy 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241000172473 Myotis ater Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000002639 bone cement Substances 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 239000013527 degreasing agent Substances 0.000 description 1
- 238000005237 degreasing agent Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
Landscapes
- Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は植込み可能々人工骨器具、特に骨増殖誘導層又
はコーティングを含むコンポジットとして製造されたプ
ロテーゼに関する。DETAILED DESCRIPTION OF THE INVENTION Field of the Invention The present invention relates to implantable artificial bone devices, particularly prostheses manufactured as composites containing bone growth-inducing layers or coatings.
多くの骨のプロテーゼ具、例えば股関節の再構成に使わ
れる器具は、髄質の管状部の中へ固定用部分をはめ込む
ことにより又はポリメチルメタクリレートの様な骨用セ
メントに工って器具を機械的に固定することにより骨格
に接合される。しかしこれらの方法は衝撃によって又り
長期間使用の結果、器具がゆるむ傾向があるので十分満
足できるものでは力い。人工骨器具をその位置に固定す
る試みにおいて、組織の内側への成長(ingrowt
h )が使われている。Many bone prosthetic devices, such as those used in hip joint reconstruction, are mechanically attached to the device by fitting a fixation portion into a medullary tube or into a bone cement such as polymethyl methacrylate. It is joined to the skeleton by fixing it to. However, these methods are not fully satisfactory because the instruments tend to loosen due to impact or as a result of long-term use. In an attempt to secure the prosthetic bone device in place, ingrowth of tissue may occur.
h) is used.
この方法の人工器官は骨の内側への成長を助けまた新し
い骨組織の付着部位として役立つよう多孔性の表面が設
けられている。人工器官を固定するため組織の内側への
成長の方式は、種々の内部人工各器官に応用されている
。The prosthesis of this method is provided with a porous surface to aid in ingrowth of bone and to serve as an attachment site for new bone tissue. The method of tissue ingrowth to secure a prosthesis has been applied to a variety of endoprostheses.
米国特許3.98&212号は組織の内側への成長によ
る骨固定用多孔性重合体コーティングを記載している。US Patent No. 3.98 & 212 describes porous polymeric coatings for bone fixation by tissue ingrowth.
便利か多孔性重合体物質は特定の密度をもちまた特定の
平均直径をもつ相互に連結された孔をもつものである。Convenient porous polymeric materials are those having interconnected pores of a specified density and a specified average diameter.
発表された重合体物質中にはある臨界・ミラメーターを
もつ高密度ポリエチレン及びポリプロピレン又はその混
合物がある。コーティングは器具に機械的に固定され又
は化学的に結合されることも示されている。Among the polymeric materials that have been published are high density polyethylene and polypropylene or mixtures thereof with certain criticality millimeters. It has also been shown that the coating may be mechanically fixed or chemically bonded to the device.
同様に米国特許4164.794号の人工骨器具は海綿
状および皮質状の骨スはキュール(1pset+lem
)の内側への成長に適応しているまた誘導性であると
いわれる特殊な性質をもつ多孔質熱可塑性物質で被覆さ
れている。Similarly, the prosthetic bone device of U.S. Pat.
) is coated with a porous thermoplastic material that has special properties that are said to be inductive.
米国特許4202055号に記載のエンドプロテーゼ具
の固定部分はセラミック粒子が添加されている非多孔性
重合体膜をもっている。セラミック粒子の再吸収により
新規形成骨の浸透した連続孔をもつ重合体構造が生成さ
れる。The fixation part of the endoprosthesis device described in US Pat. No. 4,202,055 has a non-porous polymeric membrane doped with ceramic particles. Resorption of the ceramic particles creates a polymeric structure with continuous pores infiltrated by the newly formed bone.
米国特許4713.076号によれば人工骨器具の固定
部分は新しい骨組織の迅速で深い内側への成長を可能に
しまた骨内部への檀込み物を固定するといわれる完全に
再吸収可能なコーティングをもつ。そのコーティング組
成物は高度に多孔性の球状粒子のかたちにつくられたカ
ルシウム化合物、例えばりん酸三カルシウム又はアパタ
イト(ヒドロキシルアパタイト)からできており、それ
はポリアミノ藪、ポリラクテート、ポリグリコレート、
これらの物質の共縮合物、ゼラチン又はコラーゲンの様
な再吸収性で且つ生物学的に適合する結合剤に埋め込ま
れている。According to U.S. Pat. No. 4,713.076, the anchoring portion of the prosthetic bone device is coated with a fully resorbable coating that is said to allow rapid and deep ingrowth of new bone tissue and to secure implants within the bone. have. The coating composition is made of calcium compounds, such as tricalcium phosphate or apatite (hydroxylapatite), made into highly porous spherical particles, which include polyamino tufts, polylactates, polyglycolates,
Cocondensates of these materials are embedded in resorbable and biologically compatible binders such as gelatin or collagen.
被覆された人工骨器具の他の型式のものが、米国特許式
80&606号、4159.358号、4,168,3
26号、4 35.069号、4365.356号、4
,491,987号、4652459号、4,702,
930号、および 4705゜694号に記載されてい
る。Other types of coated prosthetic bone devices are disclosed in U.S. Pat.
No. 26, 4 No. 35.069, No. 4365.356, 4
, 491,987, 4652459, 4,702,
No. 930, and No. 4705°694.
例えば脱ミネラル化された同種の又は異種の骨から見ら
れた粉砕された外来性の骨増殖物質の使用も知られてい
る。The use of comminuted exogenous bone growth material, eg found from demineralized homogeneous or xenogeneic bone, is also known.
これについては米国特許4485.097号、4678
.470号および4743.259号;ボランダーらの
°部分的損傷治療における脱ミネラル化骨マトリックス
の使用” TheJournal of Bon@
and Jolnt Surgery、 68−A巻
、ム8.1264−1273は−ジ:グロワツキーら2
33−241 (1985);ゲプスタインらの°粉末
状の脱ミネラル化骨マトリックスによる骨の大欠陥の架
橋化”Th@ Jotlrnal of Bone
and Bone Surgery。No. 4,485,097 and 4,678.
.. 470 and 4743.259; “Use of demineralized bone matrix in the treatment of partial lesions” by Bolander et al. “The Journal of Bon@
and Jolnt Surgery, Volume 68-A, Volume 8.1264-1273: Glowacki et al. 2
33-241 (1985); Gepstein et al. “Bridging large bone defects with powdered demineralized bone matrix” Th@ Jotlrnal of Bone
and Bone Surgery.
69−A巻、扁7.984−991 (1987);メ
ロニツヒの”人の歯根膜欠陥への植込み物質としての脱
石灰化した凍結乾燥骨アログラフト” The In
ternational。Vol. 69-A, B. 7.984-991 (1987); "Demineralized Freeze-dried Bone Allograft as Implant Material for Human Periodontal Ligament Defects" by Melonitz The In
international.
Journal of Psriodonties
and Rs+5tsrativeDenti@
try、 41−55は−ジ(1984,6月)およ
びカバンらの”脱ミネラル化した骨檀込みによる顎欠陥
の治療I″ Journal of 0ral an
d MaxillsfacialSurgsry、を参
照されたい。しかしこれらの人工骨成分と粉末の骨物質
に基づく骨増殖誘導成分との組合せについては従来の記
述は何の示唆も与えてくれない。Journal of Psriodonties
and Rs+5tsrativeDenti@
Try, 41-55, "Treatment of Jaw Defects by Demineralized Bone Inclusion I" by George (June 1984) and Kaban et al., Journal of Oral An.
d Maxills Facial Surgery. However, conventional descriptions do not give any suggestions regarding the combination of these artificial bone components and bone growth-inducing components based on powdered bone substances.
本発明の目的は植え込み用人工骨の固定用部分(anc
ho−rag@eomponsnt )の上に骨増殖誘
導コーティング又は層をもつ人工骨植込み物の提供にあ
る。The object of the present invention is to
The present invention provides an artificial bone implant having a bone growth inducing coating or layer thereon.
本発明の目的ti%に、パイオコシノ4ティプルで且つ
再吸収可能力結合剤の中に分散せしめられた脱ミネラル
化された骨の粉末の骨形成作用をもつコーティング又は
層でもってその固定用部分が被覆されているエンドプロ
テーゼ、例−えは股関節代替物を提供することにある。The object of the present invention is to provide the fixation part with an osteogenic coating or layer of demineralized bone powder dispersed in a pyococcinoplete and in a resorbable binder. The object of the present invention is to provide a coated endoprosthesis, for example a hip joint replacement.
本発明のこれらの及びその他の目的のために、骨組織と
接触する固定用部を持つ人工骨植込み物に、その固定用
部分の少かくも1部の表面に適用されるバイオコンノく
ティプルで且つ再吸収可能な結合剤の中に分散せしめら
れた脱ミネラル化された骨の粉末からなる骨の付着増殖
を誘導するコーティングまたは層を備えている。For these and other purposes of the invention, an artificial bone implant having an anchoring portion in contact with bone tissue is provided with a biocontact tiple applied to the surface of at least a portion of the anchoring portion; A coating or layer that induces bone attachment consisting of demineralized bone powder dispersed in a resorbable binder is provided.
該結合剤が徐々に再吸収されると、このようにして形成
された空隙部は、新しく生育した骨によって占められる
ことになり、これがプロテーゼ(補綴)と前から存在し
ていた骨の組織との間を固く結合せしめることを起こす
。As the binder is gradually resorbed, the void thus created will be occupied by new bone growth, which will connect the prosthesis to the pre-existing bone tissue. To cause a strong bond between the two.
公知の補綴コーティング、例えば上記米国特許4,20
2゜055号に記載のものに含まれる骨形成作用のかい
粒子と異なり、本発明のエンドプロテーゼにおいて存在
する脱ミネラル化された骨の粉末は新しい骨の増殖を著
しく促進するところの著しい骨形成効果を与えている。Known prosthetic coatings, such as U.S. Pat.
In contrast to the osteogenic particles contained in those described in US Pat. giving an effect.
本発明を更にその具体的な態様に基づいて説明する。The present invention will be further explained based on specific embodiments thereof.
骨形成層又は骨形成コーティングに添加される脱ミネラ
ル化された粉末骨または粉砕骨は、知られた種類の物質
であり、知られた方法によって製造される。The demineralized powdered or ground bone added to the osteogenic layer or coating is of a known type and produced by known methods.
骨の好ましい脱ミネラル化方法において骨は先づ所望の
平均粒径まで粉砕された後、脱脂/消毒され、酸で脱ミ
ネラル化処理される。好ましい脱脂・消毒溶液はエタノ
ール、水溶液である。エタノールは脂質の良好な溶媒で
あり、また水は溶液を骨中により深く浸透させる良好な
親水性担体である。エタノール水溶液は栄養成長性微生
物およびビールスを殺し、骨を消毒もする。最適に脂質
を除去しそして最も短かい時間内で消毒するため、普通
食なくも約10−40%の水(即ちアルコールの様な脱
脂剤約60−90%)が脱脂・消毒溶液中に存在する必
要がある。脱脂溶液の好ましい濃度はアルコール約60
乃至854、好ましくは70%である。脱脂後、骨は0
.6 N壇烹の様なpHy4節された醪に約3時間浸漬
して脱ミネラル化をうける。同一の濃度又はちがった濃
度で使用できる他の酵としては、無機酸並びに過酢酸の
様な有模醒などがあげられる。酸処理後置の粉末は0.
1Mりん醸ナトリウム溶液の様な緩衝液で緩衝された注
射用水で洗って、PHを最終的に調節された後、最後に
残留塩酸とpん酸ナトリウムを除去するため注射用水で
洗われる。この税ミネラル化された骨の粉末は直ちに本
発明の被覆された人工骨器具の製造に使用でき、又は使
用前、無菌状態で、好ましくは凍結戦慄状態で貯蔵でき
る。In a preferred method for demineralizing bone, the bone is first ground to the desired average particle size, then degreased/disinfected and demineralized with acid. Preferred degreasing and disinfecting solutions are ethanol and aqueous solutions. Ethanol is a good solvent for lipids and water is a good hydrophilic carrier that allows solutions to penetrate deeper into bone. Aqueous ethanol solutions kill vegetative microorganisms and viruses and also disinfect bones. Approximately 10-40% water (i.e. approximately 60-90% degreasing agent such as alcohol) is present in the degreasing and disinfecting solution for optimal lipid removal and disinfection in the shortest time possible. There is a need to. The preferred concentration of the degreasing solution is approximately 60% alcohol.
854 to 854, preferably 70%. After degreasing, bones are 0
.. 6 Soak in a moromi with a pH level of 4, such as N Danpu, for about 3 hours to demineralize it. Other enzymes that can be used at the same or different concentrations include inorganic acids and synthetic ferments such as peracetic acid. The powder after acid treatment is 0.
The pH is finally adjusted by washing with water for injection buffered with a buffer such as 1M sodium phosphate solution, followed by a final wash with water for injection to remove residual hydrochloric acid and sodium phosphate. This mineralized bone powder can be used immediately to manufacture the coated prosthetic bone devices of the present invention, or it can be stored in aseptic conditions, preferably in frozen conditions, prior to use.
骸骨の粒子の大きさは、広い範囲で変えることができ。The size of the skeleton particles can vary over a wide range.
約100ミクロンから約20ミリメーター、好ましくは
約200ミクロンから約15ミリメーター(−船釣にい
って殆んどの場合に適している)の平均粒子径内で変え
ることができる。本発明の骨形成層または骨形成コーテ
ィングを提供するよう該結合剤に加えられることのでき
る骨の粉末の量は、また広い範囲で変えることができ、
約5〜約80重量膚、好ましくは約20〜約60重量%
(殆んどの場合に適している)の量で変えることができ
るう必要ならば骨の粉末は1又は2以上の方法で変性で
きる。The average particle size can vary within a range of about 100 microns to about 20 millimeters, preferably about 200 microns to about 15 millimeters (suitable for boat fishing in most cases). The amount of bone powder that can be added to the binder to provide the osteogenic layer or coating of the invention can also vary within a wide range;
About 5 to about 80% by weight, preferably about 20 to about 60% by weight
The bone powder can be modified in one or more ways if necessary, in varying amounts (suitable in most cases).
例えば骨の粉末の多孔性はそれを増加できる。また骨の
粉末に1又Vi2以上の変性剤、例えば米国特許46’
1470号に記載の様なグルタルアルデヒドで処理でき
る。他の任意の処理のうちに#′i米国特許4743.
259の方法を用いる粉末骨の蛋白質含量増大法がある
。該結合剤中に加える前に骨粉末を所望の物質溶液中に
浸漬した彼、骨粒子を乾燥して骨粒子中に種々の物質を
導入することもできる。これらの方法によシ骨粒子中に
容易に添加できる物質には、抗ウイルス性薬剤、例えに
後天性免疫不全症候群(エイズ)伝染防止に適するもの
;エリスロマイシン、パンドラジン、ネオマイシン、ペ
ニシリン、ポリミキシンB、テトラサイクリン類、ビオ
マイシン、クロロマイセチン、およびストレフトマイシ
ン、セファゾリン、アンピシリン、トブラマイシン、ク
リンダマイシン、およびゲンタマイシン等の様な抗菌剤
および(又は)抗生物質;アミノ酸、ズプチド、ビタミ
ン、無機元素、NADおよび(又は)他の栄養剤;ホル
モン;内分泌腺組織又は組繊、フラグメント;シンセサ
イザー:コラヶ゛ナーゼ、はブチダーゼ類、オキシダー
モ等の様な酵素;寮質細胞をともなったポリマー細胞の
骨組;血管形成剤およびこれら薬剤をもつポリマー担体
;コラーゲンラテス;バイオコンパチブルな表面活性剤
:抗原性形成剤:細胞骨格剤;骨形態形成蛋白質(BM
Pa)、トランスフォーミング生長因子(TCP−β)
、インスリン様増殖因子(IGD−1)の様な生物学的
活性成分;関葉エレメント;骨分解剤;抗腫瘍剤;細胸
誘引剤及び接着剤;免疫抑制剤;及び核酸があげられる
。For example, the porosity of bone powder can increase it. In addition, bone powder may be added with a denaturing agent having a Vi2 or more, such as US Pat. No. 46'
It can be treated with glutaraldehyde as described in 1470. #'i US Pat. No. 4,743. among other optional treatments.
There is a method for increasing the protein content of powdered bone using the 259 method. It is also possible to introduce various substances into the bone particles by soaking the bone powder in a solution of the desired substance before adding it to the binder and drying the bone particles. Substances that can be easily added to the bone particles by these methods include antiviral drugs, such as those suitable for preventing acquired immunodeficiency syndrome (AIDS) transmission; erythromycin, pandrazine, neomycin, penicillin, polymyxin B; Antibacterial agents and/or antibiotics such as , tetracyclines, viomycin, chloromycetin, and streftomycin, cefazolin, ampicillin, tobramycin, clindamycin, and gentamicin; amino acids, diptide, vitamins, inorganic elements, NAD and ( or) other nutrients; hormones; endocrine gland tissue or tissues, fragments; synthesizers: enzymes such as collagenases, butidases, oxidermos, etc.; polymeric cell skeletons with dormant cells; angiogenic agents; Polymeric carriers carrying these drugs; collagen lattes; biocompatible surfactants; antigenicity-forming agents; cytoskeletal agents; bone morphogenetic proteins (BM
Pa), transforming growth factor (TCP-β)
, biologically active ingredients such as insulin-like growth factor (IGD-1); mesophyll elements; osteolytic agents; anti-tumor agents; thin-chest attractants and adhesives; immunosuppressive agents; and nucleic acids.
そのような物質を該脱ミネラル化された骨の粉末に加え
るのに加えて、又はそのような付加に代わるものとして
、これらの物質及びその他の物質は、骨形成コーティン
グ又は層の結合剤中に加えられることもできる。In addition to or as an alternative to adding such materials to the demineralized bone powder, these and other materials may be incorporated into the binder of the osteogenic coating or layer. Can also be added.
任意に添加せられる物質の量は広く変更でき、最適な量
は普通実験によって特定の場合のものに容易に決定でき
る。The amounts of optionally added substances can vary widely, and optimum amounts can be readily determined for a particular case, usually by experimentation.
本発明において骨形成層又は骨形成コーティングの結合
剤として各糧のバイオコンAティプルで且つ再吸収可能
な物質すなわち、バイオエローダブル(biod@gr
adable )またはバイオエローダブル(bioe
rodabl・)な物質が利用できる。有利に使用する
ことのできるそのような物質としては、ポリグリコール
酸、ポリ乳醒、グリコリド−ラクチドコポリマー類、こ
のようなコポリマーを、1−カプロラクトンのようか1
以上の別のコポリマーすることが可能カモツマ−で修飾
したもの、ポリエチレンオキサイド−ポリエチレンテレ
フタレートコポリマー類、米国特許第4゜826.94
5号に開示されたポリエステル−アミド類、Rosan
ら、Biomaterials、4,131 (1
983)及び Leong ら、J、Biomsd、M
ater、Res、、L 9(8)、941(1985
)に開示されたポリ藪無水物、米国特許第4.826.
945号に開示されたポリエーテルグリコールベースマ
ルチブロックコポリマー類、バイオエローダブルカシア
ノアクリレート類、米国特許第4180.646号に開
示されたオルトエステルポリマー類及びオルトカルボネ
ートポリマー類、交差結合せしめられたコラーゲンまた
は交差結合化されて々いコラーゲン及びキチンがあげら
れる。In the present invention, as a binder for the osteogenic layer or osteogenic coating, a resorbable and resorbable substance, i.e., bioerodable (biod@gr.
available ) or bioero double (bioe
(rodable) materials are available. Such materials which may be advantageously used include polyglycolic acid, polydemulcent, glycolide-lactide copolymers, such as 1-caprolactone or 1-caprolactone.
Other copolymers of the above may be modified with chamozuma, polyethylene oxide-polyethylene terephthalate copolymers, U.S. Pat. No. 4,826.94.
Polyester-amides disclosed in No. 5, Rosan
et al., Biomaterials, 4,131 (1
983) and Leong et al., J., Biomsd., M.
ater, Res, L 9(8), 941 (1985
), the polybrush anhydride disclosed in U.S. Pat. No. 4,826.
Polyether glycol-based multiblock copolymers disclosed in US Pat. Examples include collagen or cross-linked collagen and chitin.
本発明に従って植え込み用人工骨に適用されることりで
きる脱ミネラル化された骨の粉末を含有するコラーゲン
を説明するため、米国特許第4485,097が参照さ
れ、そしてその内容は本明細書において参考として付は
加えられるーもし必要なら、該結合剤は、補強剤、例え
ば繊維状の補強剤または粒子状の補強剤を含んで、その
骨形成コーティングのひっばり強度を増加せしめること
ができる。Reference is made to U.S. Pat. No. 4,485,097, the contents of which are incorporated herein by reference, to describe collagen containing demineralized bone powder that can be applied to implantable bone prostheses in accordance with the present invention. Additions may be added - if desired, the binder can include reinforcing agents, such as fibrous or particulate reinforcing agents, to increase the stiffness of the osteogenic coating.
本発明を今や股関節エンドプロテーゼについて具体的に
記載するが、本発明はどんな型の骨植込み物又はその代
替物、例えば歯又は顎骨顔面の再構成に使われるものに
実施できるのである。Although the invention will now be specifically described with respect to a hip endoprosthesis, it can be implemented in any type of bone implant or substitute, such as those used in dental or maxillofacial reconstruction.
図1から5までに示すとおり知られた型の股関節人工器
官(プロテーゼ)の大腿骨費の部材1(l金属、セラミ
ックス、重合体(ポリマー)およびそれらの複合体(コ
ンポジット)等の様々種々のバイオエンジニアリング物
質から製造される。人工器官には頭物11、ネック部1
2および大腿骨50の髄質管状部内に植込み物を固定す
るための役をするステム部13がある。As shown in Figures 1 to 5, components 1 of the femoral bone of the known type of hip prosthesis are made of various materials such as metals, ceramics, polymers and composites thereof. Manufactured from bioengineered materials.The prosthesis includes a headpiece 11 and a neck part 1.
2 and a stem portion 13 which serves to secure the implant within the medullary tube of the femur 50.
図1〜3に記載された骨形成層30を適用する場合に、
大腿骨りの部材10は鋳型20の穴の部分の中に置かれ
、(かお、他のこれと合わさる鋳型に示されてい々い)
、そしてステム部13の表面と鋳型の穴の壁とで決まる
空間またはギャップ21ができ、それはそのステム部に
適用された骨形成層の形及び厚さに相当するものとなる
。When applying the osteogenic layer 30 described in FIGS. 1 to 3,
The femoral frame member 10 is placed within the hole portion of the mold 20 (as shown in other mating molds).
, and there is a space or gap 21 defined by the surface of the stem 13 and the wall of the mold hole, which corresponds to the shape and thickness of the osteogenic layer applied to the stem.
一つの便利な骨形成コーティングを付与する方法におい
ては、結合剤の可塑化された物体は、先づその中に実質
的に均一に取シ込まれている脱ミネラル化され走置と一
緒になって製造される。故に例えば結合剤がグリコリド
−ラクチドコポリマーである場合、一定の樹脂はばンゼ
ン、トルエン、キシレン等の様な適当な溶媒を用いば一
スト状に可塑化され九後、それに骨粉末が均一に添加さ
れる。流動性物質はステム部13表面に過剰につけられ
ついで人工器官を鋳型に入れ鋳型を閉じれば過剰にある
物質は金型から押出される。別の方法としては被覆され
ていないプロテーゼを鋳型の片@20に入れ、鋳型の他
のりをとシつけ固定し、可塑性骨形成性被侵用物質を空
間21内に過剰となる迄注入する。図2に示すとおシス
テム部13の周りに骨形成層30が生成した後金型から
プロテーゼをとり出し、可塑化溶媒を蒸発して、図3に
示す様な被覆されたプロテーゼが出来上り、それは消毒
し無菌貯蔵される。In one convenient method of applying an osteogenic coating, a plasticized body of binder is first combined with a demineralized mass that is substantially uniformly incorporated therein. Manufactured by Thus, for example, if the binder is a glycolide-lactide copolymer, a resin may be plasticized in one stroke using a suitable solvent such as benzene, toluene, xylene, etc., and then bone powder may be uniformly added thereto. be done. The flowable material is applied in excess to the surface of the stem portion 13, and when the prosthesis is placed in the mold and the mold is closed, the excess material is forced out of the mold. Alternatively, the uncovered prosthesis is placed in the mold piece 20, the rest of the mold is tamed and secured, and the plastic osteogenic invasive material is injected into the space 21 until there is an excess. After the formation of the osteogenic layer 30 around the system part 13 as shown in FIG. 2, the prosthesis is removed from the mold and the plasticizing solvent is evaporated, resulting in a coated prosthesis as shown in FIG. 3, which is disinfected. and stored aseptically.
エンドプロテーゼ10の固定用部分に骨形成性コーテン
グ30をつける他の方法において、結合剤は1例えば、
脱ミネラル仕置粉末粒径とほぼ同じ平均粒径をもつ微粉
末として用意され、骨の粉末は結合剤粉末と均一混合さ
れて乾燥した易流動性粉末混合物とされた後、鋳型20
の空間21内に過剰に入れられる。次いで粉末混合物を
自己支持性付着コーテングを形収するところの温度、例
えば結合剤粒子が溶着して1体となるに十分カ温iまで
加熱彼、大気温まで冷却して本発明の被膜付き人工器官
かえられるのである。In another method of applying the osteogenic coating 30 to the fixation portion of the endoprosthesis 10, the bonding agent is one, e.g.
Prepared as a fine powder with an average particle size approximately the same as the demineralized powder particle size, the bone powder is uniformly mixed with the binder powder to form a dry, free-flowing powder mixture, and then molded into the mold 20.
is placed in excess in the space 21 of. The powder mixture is then heated to a temperature that will form a self-supporting adhesive coating, such as sufficiently warm to cause the binder particles to weld together, and cooled to ambient temperature to form a coated artificial coating of the present invention. Organs can be changed.
骨形成性コーティング30は先づステム部に結合剤の溶
媒溶液を付与し溶媒を1部蒸発してぺたべたした膜とし
た後、脱ミネラル化された骨の粉末を結合剤と接触させ
てそれにつけることによってステム部13の表面に付与
できる。The osteogenic coating 30 is prepared by first applying a solvent solution of a binder to the stem portion, evaporating a portion of the solvent to form a sticky film, and then contacting demineralized bone powder with the binder. By attaching it thereto, it can be applied to the surface of the stem portion 13.
この方法を数回反復することにより予定の厚さの膜に生
成できる。溶媒を完全蒸発させて骨形成性膜が完成する
。By repeating this method several times, a film of desired thickness can be produced. The osteogenic membrane is completed by complete evaporation of the solvent.
結合剤として可溶性コラーゲンを用いてそのベース上に
骨形成層が付与されるのに特に適した別の方法は、脱ミ
ネラル化された骨の粉末を懸濁したコラーゲンの水性ゲ
ル中にそのプロテーゼを浸漬し、次にゲルを乾燥し、必
要なら公知の方法に従ってホルムアルデヒドのような交
差結合化剤を用いてそのコラーゲンバインダーを所望の
程度にまで交差結合化するものである。Another method, particularly suitable for imparting an osteogenic layer on its base using soluble collagen as a binder, is to place the prosthesis in an aqueous gel of collagen in which demineralized bone powder is suspended. After soaking, the gel is then dried and the collagen binder is cross-linked to the desired degree, if necessary, using a cross-linking agent such as formaldehyde according to known methods.
骨形成性膜又は層の厚さに特に重要ではない。平均厚さ
約1乃至約50ミル、好ましくは約10乃至約40ミル
で一般に潰足な結果かえられるっ
必要ならば人工器官、例えば骨形成性コーティング又は
層をつけようとするステム部13の表面は、それへ上記
コーティング又は層がよく付着する様1又は2回以上あ
らかじめの処理をしてもよい。例えば人工器官表面に米
国特許4.778.469号紀載り様な付着促進パター
ン又は米国特許4,159,358号記藍記載な付着促
進用の粗表面形態を与えることができる。The thickness of the osteogenic membrane or layer is not particularly critical. An average thickness of about 1 to about 50 mils, preferably about 10 to about 40 mils, will generally result in the collapse of the surface of the stem portion 13 to which a prosthesis, such as an osteogenic coating or layer, is to be applied if necessary. may be pretreated one or more times to ensure good adhesion of the coating or layer thereto. For example, the prosthesis surface can be provided with an adhesion-promoting pattern as described in US Pat. No. 4,778,469 or a rough surface morphology to promote adhesion as described in US Pat.
次なる実施例は、本発明の植え込み用人工骨及び骨形成
コーティング組成物を具体的に説明するためのものであ
る。The following examples are intended to specifically illustrate the implantable artificial bone and osteogenic coating compositions of the present invention.
実施例
人、脱ミネラル化された皮質性骨粉末の製造粉砕し平均
径約100乃至約300ミクロンに篩分けした皮質性骨
の一定量を反応器に入れ蓋をした。骨のグラム当り30
−の割合の70−エタノール溶液を入れた後、1時間撹
拌して(ボランダーらの Journal of B
oneand Joint Surgery、 68−
A巻A8(1986゜10月))、骨の粉末の脱脂と消
毒をした。エタノールを排出した後置のグラム当り50
−の0.6N塩酸溶液を反応器に入れ(ボランダーら、
上記)、3時間反応させた。(ブロワツキ−、AATB
WorkIIhop、 11回年会(1987))、
塩醸を排出し注射用水(WF I )を入れWFIを5
分間隔で3回、とりかえ洗浄したっWFIを排出し、骨
をα1Mりん酸ナトリウム溶液に浸漬し、溶液pHがa
8乃至7.4となる迄反復した。WFI洗浄法を反復し
て脱ミネラル化皮質性前粉末をえて次の用途に使用でき
た。EXAMPLE Preparation of Demineralized Cortical Bone Powder A fixed amount of ground and sieved cortical bone having an average diameter of about 100 to about 300 microns was placed in a reactor and capped. 30 per gram of bone
-, then stirred for 1 hour (Bolander et al., Journal of B
one and joint surgery, 68-
Volume A, A8 (October 1986)), the bone powder was degreased and sterilized. 50 per gram of post-exhaust ethanol
- into the reactor (Bolander et al.,
above), the reaction was carried out for 3 hours. (Browacki, AATB
Work II hop, 11th annual meeting (1987)),
Drain the salt brew and add water for injection (WFI) to 5 WFI.
Drain the WFI and immerse the bone in a 1M sodium phosphate solution until the pH of the solution is a.
It was repeated until the value was 8 to 7.4. The WFI washing procedure was repeated to obtain a demineralized pre-cortical powder that could be used in subsequent applications.
B、股関節エンドプロテーゼのステム部への脱ミネラル
化グリコリド−ラクチドコポリマーのキシレン液である
結合剤液を、20重量%のグリコリド−ラクチドコポリ
マー(約20モルチのグリコリド)の粉末を80重量%
のキシレンに溶解することにより製造した。股関節プロ
テーゼのステム部を結合剤溶液に浸漬し、溶液を乾かし
てべたべたとし、その結合剤表面に骨粉床をふりかけて
付着させた。B. Applying a binder solution, which is a xylene solution of demineralized glycolide-lactide copolymer to the stem of a hip endoprosthesis, and adding 20% by weight of a powder of glycolide-lactide copolymer (approximately 20 moles of glycolide) to 80% by weight.
was prepared by dissolving it in xylene. The stem of the hip prosthesis was immersed in a binder solution, the solution was allowed to dry to a sticky consistency, and a bed of bone powder was sprinkled onto the binder surface to adhere.
この方法を数回反復して人工骨ステム部表面上に脱ミネ
ラル化された皮質性骨粉末約40乃至約50重量%を含
む平均厚さ約2−3−の骨形成性層を形成した。乾燥室
中で溶媒の完全蒸発後、被膜付き人工器官は知られた普
通の方法で消毒され包装された。This process was repeated several times to form an osteogenic layer with an average thickness of about 2-3 inches containing about 40 to about 50% by weight of demineralized cortical bone powder on the surface of the artificial bone stem. After complete evaporation of the solvent in a drying chamber, the coated prosthesis was sterilized and packaged in a known and conventional manner.
添付図面において各番号は、それぞれ同一の部品を示し
ている。
図1〜3は、股関節エンドプロテーゼの大腿骨側部の固
定部材に、骨の増殖を誘導するコーティングを適用した
場合の一例の各段階での側面図を順番に示したものであ
る。
図4Fi、図3の股関節エンドプロテーゼに適用された
ような骨の増殖を誘導するコーティングの拡大断面を示
すものである。
図5は、大腿骨の髄質管状部内に看かれた被覆されてい
る股関節エンドプロテーゼの挿入状態を示すものである
。In the accompanying drawings, each number indicates the same part. 1 to 3 sequentially show side views at various stages of an example in which a coating that induces bone growth is applied to a fixing member on the femoral side of a hip joint endoprosthesis. Figure 4Fi shows an enlarged cross-section of a bone growth-inducing coating as applied to the hip endoprosthesis of Figure 3; FIG. 5 shows the insertion of a covered hip endoprosthesis viewed within the medullary canal of a femur.
Claims (13)
で且再吸収可能な結合剤中に分散された脱ミネラル化さ
れた骨の粉末からなる骨形成組成物の接着性コーテイン
グを有していることを特徴とする人工骨器具。1. that the fixation portion of the prosthetic bone device has an adhesive coating of an osteogenic composition consisting of demineralized bone powder dispersed in a biocompatible and resorbable binder; Characteristic artificial bone devices.
ミクロン乃至約200ミリメーターである請求項1に記
載の人工骨器具。2. The average particle size of demineralized bone powder is approximately 100
The prosthetic bone device of claim 1, which is between microns and about 200 millimeters.
ミクロン乃至約15ミリメーターである請求項1に記載
の人工骨器具。3. The average particle size of demineralized bone powder is approximately 200
The prosthetic bone device of claim 1, which is between microns and about 15 millimeters.
脱ミネラル化された骨の粉末を含む請求項1に記載の人
工骨器具。4. The prosthetic bone device of claim 1, wherein the osteogenic coating comprises from about 5 to about 80% by weight demineralized bone powder.
の脱ミネラル化された骨の粉末を含む請求項1に記載の
人工骨器具。5. The osteogenic coating is about 20 to about 60% by weight.
2. The prosthetic bone device of claim 1, comprising demineralized bone powder.
ら誘導されたものである請求項1に記載の人工骨器具。6. The artificial bone device according to claim 1, wherein the demineralized bone powder is derived from cortical bone (bone cortex).
リド−ラクチドコポリマー、グリコリド−ラクチドコポ
リマーであつて、それと共重合可能な一種以上のモノマ
ーでもつて修飾されたもの、ポリエチレンオキサイド−
ポリエチレンテレフタレートコポリマー、ポリエステル
アミド、ポリ酸無水物、ポリエーテルグリコールベース
のマルチブロツクコポリマー、バイオエロ−ダブルなシ
アノアクリレート、オルトエステルポリマー、オルトカ
ルボネートポリマー、交差結合したあるいは交差結合し
ていないコラーゲン及びキチンからなる群から選ばれた
ものである請求項1に記載の人工骨器具。7. The binder is polygolic acid, polylactic acid, glycolide-lactide copolymer, glycolide-lactide copolymer modified with one or more monomers copolymerizable therewith, polyethylene oxide-
Polyethylene terephthalate copolymers, polyesteramides, polyanhydrides, polyether glycol-based multiblock copolymers, bioerodible cyanoacrylates, orthoester polymers, orthocarbonate polymers, crosslinked and non-crosslinked collagen and chitin. The artificial bone device according to claim 1, which is selected from the group consisting of.
及び強化粒子より成る群からえらばれた少なくとも1つ
の追加成分を含有する請求項1に記載の人工骨器具。8. The prosthetic bone device of claim 1, wherein the osteogenic layer or coating contains at least one additional component selected from the group consisting of reinforcing fibers and reinforcing particles.
ス剤、抗菌剤、抗生物質、アミノ酸、ペプチド、ビタミ
ン、無機元素、NAD、ホルモン、内分泌腺組織、シン
セサイザー、酵素、実質細胞をともなつたポリマー細胞
の骨組形成剤、血管形成剤、重合性薬物担体、コラーゲ
ンラテス、抗原性形成剤、細胞骨格剤、生物学的活性成
分、間葉剤、骨分解剤、抗腫瘍剤、細胞誘引剤、細胞接
着剤、免疫抑制剤、および核酸より成る群からえらばれ
た少なくも1つの追加成分を該骨の粒子または該結合剤
またはその両者に加えられて含有するものである請求項
1に記載の人工骨器具。9. The osteogenic layer or coating contains polymeric cells with antiviral agents, antibacterial agents, antibiotics, amino acids, peptides, vitamins, inorganic elements, NAD, hormones, endocrine tissue, synthesizers, enzymes, parenchymal cells. Skeleton forming agents, angiogenic agents, polymerizable drug carriers, collagen lattes, antigenicity forming agents, cytoskeleton agents, biologically active ingredients, mesenchymal agents, osteolytic agents, antitumor agents, cell attractants, cell adhesives The artificial bone device of claim 1, further comprising at least one additional component selected from the group consisting of , an immunosuppressant, and a nucleic acid in addition to the bone particles or the binding agent or both. .
求項1に記載の人工骨器具。10. The prosthetic bone device of claim 1, wherein the osteogenic layer has a thickness of about 1 to about 50 mils.
請求項1に記載の人工骨器具。11. The prosthetic bone device of claim 1, wherein the osteogenic layer has a thickness of about 10 to about 40 mils.
着促進面が設けられているところの請求項1に記載の人
工骨器具。12. The artificial bone device according to claim 1, wherein the fixation portion is provided with an adhesion promoting surface before application of the osteogenic composition.
ーゼである請求項1に記載の人工骨器具。13. The prosthetic bone device of claim 1, wherein the device is an orthopedic, dental, or maxillofacial prosthesis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21594890A JPH0497747A (en) | 1990-08-17 | 1990-08-17 | Artificial bone for transplanting application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21594890A JPH0497747A (en) | 1990-08-17 | 1990-08-17 | Artificial bone for transplanting application |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0497747A true JPH0497747A (en) | 1992-03-30 |
Family
ID=16680907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP21594890A Pending JPH0497747A (en) | 1990-08-17 | 1990-08-17 | Artificial bone for transplanting application |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0497747A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004515318A (en) * | 2000-12-14 | 2004-05-27 | オステオテック インコーポレーテッド | Method for producing demineralized bone particles |
US7959941B2 (en) | 2001-10-12 | 2011-06-14 | Warsaw Orthopedic, Inc. | Bone graft comprising a demineralized bone matrix and a stabilizing agent |
US8002813B2 (en) | 1999-10-15 | 2011-08-23 | Warsaw Orthopedic, Inc. | Volume maintaining osteoinductive/osteoconductive compositions |
US8268008B2 (en) | 2003-06-11 | 2012-09-18 | Warsaw Orthopedic, Inc. | Osteoimplants and methods for their manufacture |
US9999520B2 (en) | 2000-07-19 | 2018-06-19 | Warsaw Orthopedic, Inc. | Osteoimplant and method of making same |
-
1990
- 1990-08-17 JP JP21594890A patent/JPH0497747A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8002813B2 (en) | 1999-10-15 | 2011-08-23 | Warsaw Orthopedic, Inc. | Volume maintaining osteoinductive/osteoconductive compositions |
US8197474B2 (en) | 1999-10-15 | 2012-06-12 | Warsaw Orthopedic, Inc. | Volume maintaining osteoinductive/osteoconductive compositions |
US9999520B2 (en) | 2000-07-19 | 2018-06-19 | Warsaw Orthopedic, Inc. | Osteoimplant and method of making same |
JP2004515318A (en) * | 2000-12-14 | 2004-05-27 | オステオテック インコーポレーテッド | Method for producing demineralized bone particles |
US7959941B2 (en) | 2001-10-12 | 2011-06-14 | Warsaw Orthopedic, Inc. | Bone graft comprising a demineralized bone matrix and a stabilizing agent |
US8268008B2 (en) | 2003-06-11 | 2012-09-18 | Warsaw Orthopedic, Inc. | Osteoimplants and methods for their manufacture |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5061286A (en) | Osteoprosthetic implant | |
Damien et al. | Bone graft and bone graft substitutes: a review of current technology and applications | |
CA2353240C (en) | Bone material and collagen combination for repair of injured joints | |
EP0880345B1 (en) | Process for producing flexible sheets from demineralized, elongate, bone particles | |
US6478825B1 (en) | Implant, method of making same and use of the implant for the treatment of bone defects | |
US7001551B2 (en) | Method of forming a composite bone material implant | |
US6843807B1 (en) | Osteoimplant | |
US10821207B2 (en) | Composite materials for bone repair based on decellularized biological tissue matrix material and the preparation method thereof | |
JP2004358249A (en) | Strontium-substituted apatite coating | |
US11324597B2 (en) | Implantable composite containing carbonated hydroxyapatite | |
JPH04246359A (en) | Osteogenic composition and interplanted tissue containing it | |
JP2002522157A (en) | Osteoinduction of cortical bone allograft by coating with biopolymer seeded with recipient periosteal bone cells | |
JPH06225894A (en) | Hollow internal protease with filler to promote growth of bone | |
US6998135B1 (en) | Demineralized corticocancellous bone sheet | |
KR20000075463A (en) | Bone substitute material with a surface coating of peptides having an rgd amino acid sequence | |
JPH0497747A (en) | Artificial bone for transplanting application | |
EP0470305A1 (en) | Osteoprosthetic implant | |
US20090098092A1 (en) | Composite Bone Material and Method of Making and Using Same | |
US20220008620A1 (en) | Bone sialoprotein functionalized materials for directed bone regeneration | |
JP2012505704A (en) | Method and system for attaching a mimetic growth agent to a medical insert | |
KR20210145130A (en) | Improved bone implant matrix comprising proline-rich peptide and method for preparing same | |
US10183095B2 (en) | Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate | |
US7384652B2 (en) | Complexed-acidic-phospholipid-collagen composites for bone induction |